WASHINGTON — Facing hostility from nearly every corner of Capitol Hill, drug makers have spent recent weeks aggressively courting a group of business-friendly Democrats.

PhRMA and BIO, the two major drug industry trade groups, met last week with the New Democrat Coalition, according to multiple Democratic aides. The group, which includes more than 100 members and describes itself as politically moderate and “pro-growth,” has also scheduled meetings with the drug companies Pfizer and Genentech, as well as the California Life Sciences Association (CSLA), which represents drug makers including AbbVie and Allergan.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What is missing are Members of Congress who can combine measures to lower prices with measures to enhance innovation, by increasing grants (increasing NIH budget), subsidizing (restoring ODTC, etc) and rewards for successful R&D (Market Entry Rewards), without relying upon high prices and extended monopolies. Weaning the industry from high prices requires a build-out of R&D measures delinked from prices.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy